Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
MA 2029 is a novel, selective and competitive motilin receptor antagonist, which inhibits motilin-induced intestinal contractions in animals models. MA 2029 may be useful for gastrointestinal disorders associated with disturbed gastrointestinal motility such as IBS.
?您的位置：
